Welcure Drugs & Pharmaceuticals Ltd.
BSE: 524661
₹0.24
₹-0.01
(-4.00%)
As on 02-Sep-2026IST
Market cap
₹30 Cr
Revenue (TTM)
₹366 Cr
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-17 Cr
-
ROE
4.2 %
-
ROCE
2.5 %
-
Industry P/E
--
-
EV/EBITDA
-27.9
-
Debt to Equity
0.9
-
Book Value
₹0.8
-
EPS
₹1.7
-
Face value
1
-
Shares outstanding
1,235,940,200
10 Years Aggregate
CFO
₹-222.04 Cr
EBITDA
₹0.71 Cr
Net Profit
₹2.26 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Welcure Drugs
| -42.9 | 0.0 | -14.3 | -71.5 | -11.4 | -11.2 | 1.5 |
|
BSE Healthcare
| 18.0 | 0.9 | 10.3 | 17.1 | 22.7 | 14.0 | 12.3 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Welcure Drugs
| -58.3 | 195.4 | -31.0 | -26.2 | 234.6 | 353.1 | -5.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Welcure Drugs
|
0.2 | 29.7 | 365.5 | -17.0 | -2.0 | -14.3 | -- | 0.3 |
| 160.9 | 202.3 | 38.2 | 9.8 | -- | 99.6 | 16.9 | -- | |
| 1,797.4 | 7,832.9 | 7,127.9 | 167.7 | 3.7 | 7.6 | 62.5 | 4.5 | |
| 40.9 | 39.3 | 31.2 | 4.1 | -- | 39.4 | 9.5 | 1.6 | |
| 26.7 | 34.2 | 12.6 | -1.8 | -77.2 | -1.6 | -- | 0.3 | |
| 22.0 | 31.2 | 49.7 | 4.1 | -- | 29.1 | 5.2 | 0.8 | |
| 32.3 | 20.3 | -3.0 | -0.1 | 17.3 | -0.7 | -- | 2.0 | |
| 36.0 | 19.7 | 562.1 | 1.2 | 0.4 | 9.8 | 15.9 | 10.4 | |
| 148.5 | 130.5 | 58.3 | 8.6 | -- | 37.9 | 10 | 1.8 | |
| 69.0 | 134.8 | 106.8 | 4.8 | -- | 14.9 | 26.9 | -- |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Welcure Drugs
Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical goods in India. The company was incorporated in 1996 and is based in Delhi, India.
-
Incorporated
1996
-
Chairman
--
-
Managing Director
Chintan Didawala
-
Headquarters
Delhi, Delhi
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Welcure Drugs
What is the current share price of Welcure Drugs & Pharmaceuticals Ltd Today?
The share price of Welcure Drugs & Pharmaceuticals Ltd is ₹0.24 (BSE) as of 02-Sep-2026 IST. Welcure Drugs & Pharmaceuticals Ltd has given a return of -11.43% in the last 3 years.
What is the current PB & PE ratio of Welcure Drugs & Pharmaceuticals Ltd?
Since, TTM earnings of Welcure Drugs & Pharmaceuticals Ltd is negative, P/E ratio is not available.
The P/B ratio of Welcure Drugs & Pharmaceuticals Ltd is 0.31 times as on 02-Sep-2026, a 0 premium to its peers’ median range of 0.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
4.28 |
1.00 |
2024 |
0.00 |
3.77 |
2023 |
52.97 |
3.57 |
2022 |
501.03 |
127.31 |
2021 |
41.32 |
32.82 |
What is the 52 Week High and Low of Welcure Drugs & Pharmaceuticals Ltd?
The 52-week high and low of Welcure Drugs & Pharmaceuticals Ltd are Rs 0.96 and Rs 0.19 as of 03-Sep-2026.
What is the market cap of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹ 30 Cr as on 02-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Welcure Drugs & Pharmaceuticals Ltd?
Before investing in Welcure Drugs & Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.